

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

**PrMINT-ONDANSETRON SOLUTION**

Ondansetron Oral Solution

Solution, 4 mg / 5 ml ondansetron (as ondansetron hydrochloride dihydrate), Oral  
House Standard

Antiemetic

5-HT<sub>3</sub> receptor antagonist

ATC code A04AA01

Mint Pharmaceuticals Inc.  
6575 Davand Drive  
Mississauga, Ontario  
L5T 2M3

Date of Initial Authorization:  
January 10, 2022

Date of Revision:  
September 13, 2022

Submission Control Number: 261685

## RECENT MAJOR LABEL CHANGES

<a href="#">1 INDICATIONS, Adults (18-64 years of age)</a>	09/2022
<a href="#">4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment</a>	09/2022
<a href="#">7 WARNINGS AND PRECAUTIONS, Cardiovascular, Myocardial Ischemia and Coronary Artery Spasm</a>	09/2022
<a href="#">7 WARNINGS AND PRECAUTIONS, Special Populations, 7.1.1 Pregnant Women</a>	01/2022

## TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES .....	2
TABLE OF CONTENTS .....	2
<b>PART I: HEALTH PROFESSIONAL INFORMATION .....</b>	<b>4</b>
<b>1 INDICATIONS .....</b>	<b>4</b>
1.1 Pediatrics (<18 years of age) .....	4
1.2 Geriatrics (>65 years of age) .....	4
<b>2 CONTRAINDICATIONS .....</b>	<b>4</b>
<b>4 DOSAGE AND ADMINISTRATION .....</b>	<b>5</b>
4.1 Dosing Considerations .....	5
4.2 Recommended Dose and Dosage Adjustment .....	5
<b>5 OVERDOSAGE .....</b>	<b>7</b>
<b>6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.....</b>	<b>8</b>
<b>7 WARNINGS AND PRECAUTIONS.....</b>	<b>8</b>
7.1 Special Populations .....	11
7.1.1 Pregnant Women .....	11
7.1.2 Breast-feeding .....	11
7.1.3 Pediatrics .....	11
7.1.4 Geriatrics .....	11
<b>8 ADVERSE REACTIONS .....</b>	<b>11</b>
8.2 Clinical Trial Adverse Reactions .....	11
8.5 Post-Market Adverse Reactions.....	12
<b>9 DRUG INTERACTIONS .....</b>	<b>14</b>

9.1	Serious Drug Interactions.....	14
9.2	Drug Interactions Overview .....	14
9.4	Drug-Drug Interactions .....	14
9.5	Drug-Food Interactions .....	16
9.6	Drug-Herb Interactions .....	16
9.7	Drug-Laboratory Test Interactions.....	16
<b>10</b>	<b>CLINICAL PHARMACOLOGY .....</b>	<b>16</b>
10.1	Mechanism of Action.....	16
10.2	Pharmacodynamics .....	16
10.3	Pharmacokinetics .....	19
<b>11</b>	<b>STORAGE, STABILITY AND DISPOSAL.....</b>	<b>21</b>
<b>PART II: SCIENTIFIC INFORMATION .....</b>		<b>22</b>
<b>13</b>	<b>PHARMACEUTICAL INFORMATION .....</b>	<b>22</b>
<b>14</b>	<b>CLINICAL TRIALS.....</b>	<b>22</b>
14.1	Trial Design and Study Demographics .....	22
14.2	Study Results .....	22
<b>16</b>	<b>NON-CLINICAL TOXICOLOGY .....</b>	<b>23</b>
<b>17</b>	<b>SUPPORTING PRODUCT MONOGRAPHS.....</b>	<b>28</b>
<b>PATIENT MEDICATION INFORMATION .....</b>		<b>29</b>

## PART I: HEALTH PROFESSIONAL INFORMATION

### 1 INDICATIONS

#### Adults (18-64 years of age)

MINT-ONDANSETRON SOLUTION (ondansetron hydrochloride dihydrate) is indicated for:

- the prevention of nausea and vomiting associated with mildly and moderately emetogenic chemotherapy and radiotherapy.
- the maintenance of anti-emesis following intravenous doses of ondansetron used for the prevention of nausea and vomiting associated with highly emetogenic chemotherapy, including cisplatin.
- the prevention of post-operative nausea and vomiting.

#### 1.1 Pediatrics (<18 years of age)

##### Prevention of Post-Chemotherapy Induced Nausea and Vomiting

- **Pediatrics (4-12 years of age):** Ondansetron hydrochloride dihydrate was effective and well tolerated when given to children 4-12 years of age
- **Pediatrics (<4 years of age):** MINT-ONDANSETRON SOLUTION is not indicated for the treatment of children less than 4 years old.

##### Prevention of Post-Radiotherapy Induced Nausea and Vomiting

MINT-ONDANSETRON SOLUTION is not indicated for this use in any pediatric population.

##### Prevention of Post-Operative Nausea and Vomiting

MINT-ONDANSETRON SOLUTION is not indicated for this use in any pediatric population.

#### 1.2 Geriatrics (>65 years of age)

##### Prevention of Post-Chemotherapy and Radiotherapy Induced Nausea and Vomiting

Efficacy and tolerance of ondansetron hydrochloride were similar to that observed in younger adults. [See 4.2 Recommended Dose and Dosage Adjustment, Chemotherapy induced Nausea and Vomiting, Use in Elderly; 7. WARNINGS AND PRECAUTIONS, Cardiovascular; 7.1.4 Geriatrics; 10.3 Pharmacokinetics, Geriatrics.](#)

##### Prevention of Post-Operative Nausea and Vomiting

Clinical experience in the use of ondansetron hydrochloride dihydrate in the prevention and treatment of post-operative nausea and vomiting is limited; MINT-ONDANSETRON SOLUTION is not indicated for this use in the geriatric population.

### 2 CONTRAINDICATIONS

- MINT-ONDANSETRON SOLUTION (ondansetron hydrochloride) is contraindicated in patients with a history of hypersensitivity to the drug or any components of its

formulations. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).

- The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron.

## 4 DOSAGE AND ADMINISTRATION

### 4.1 Dosing Considerations

**Note: Mint Pharmaceuticals Inc. only markets MINT-ONDANSETRON SOLUTION as an oral solution. When injectable ondansetron is used, the product monograph for ondansetron hydrochloride dihydrate injection should be consulted.**

Ondansetron hydrochloride dihydrate clearance is reduced in patients with moderate or severe hepatic impairment. Their total daily dose should not exceed 8 mg. See [7 WARNINGS AND PRECAUTIONS, Hepatic](#).

Ondansetron hydrochloride dihydrate has important cardiac side-effects (dose-dependent QTc prolongation, coronary artery spasm, myocardial ischemia, and sequelae). These effects are reported more often with intravenous administration and are expected to be greater with a faster rate of infusion. See [7 WARNINGS AND PRECAUTIONS, Cardiovascular, QTc Interval Prolongation; and Myocardial Ischemia and Coronary Artery Spasm; 9.4 Drug-Drug Interactions, QTc-Prolonging Drugs; 10.2 Pharmacodynamics, Electrocardiography](#).

Though Ondansetron hydrochloride dihydrate efficacy and tolerance were similar for elderly compared to younger adults in chemotherapy clinical trials, exposure-response modelling predicted a greater effect on QTcF in patients  $\geq 75$  years of age compared to young adults. See [10.3 Pharmacokinetics, Geriatrics](#).

Dosing considerations that reduce cardiac risks:

- Use the minimum effective dose.
- Use oral formulations if possible (lower C<sub>max</sub>).

### 4.2 Recommended Dose and Dosage Adjustment

#### **Prevention of Highly Emetogenic Chemotherapy Induced Nausea and Vomiting**

MINT-ONDANSETRON SOLUTION is not indicated for this use.

#### **Maintenance of Anti-Emesis Following Intravenous Doses of Ondansetron Used for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy**

- **Adults:**

For the maintenance of anti-emesis established by intravenous ondansetron:

- 8 mg orally every 8 hours, for up to 5 days; following the first 24 hours

- **Pediatrics (<18 years of age):**

- MINT-ONDANSETRON SOLUTION is not indicated for this use in children under 18 years of age.

### **Prevention of Less Emetogenic Chemotherapy Induced Nausea and Vomiting**

*Caution: To reduce cardiac risks, carefully follow the dosing guidelines under [4.1 Dosing Considerations](#).*

- **Adults:**

- 8 mg orally, 1-2 hours prior to chemotherapy followed by 8 mg orally, twice daily for up to 5 days.

- **Pediatrics (4-<18 years of age):**

- Following chemotherapy: 4 mg orally, every 8 hours.
  - For prevention of chemotherapy induced nausea and vomiting in children 4-18 years of age, intravenous ondansetron should be administered 30 minutes before chemotherapy. **Note: MINT-ONDANSETRON SOLUTION is only available as an oral solution. A product monograph for ondansetron hydrochloride injection should be consulted.**

- **Pediatrics (<4 years of age):**

MINT-ONDANSETRON SOLUTION is not indicated for this use in children under 4 years of age.

- **Geriatrics (≥65 years of age):**

Efficacy and tolerance in patients aged over 65 years were similar to that seen in younger adults indicating no need to alter dosage schedules in this population (See [10.3 Pharmacokinetics, Geriatrics](#).)

### **Prevention of Radiotherapy Induced Nausea and Vomiting:**

*Caution: To reduce cardiac risks, carefully follow the dosing guidelines under [4.1 Dosing Considerations](#).*

- **Adults:**
  - 8 mg orally, given 1 to 2 hours before radiotherapy followed by 8 mg orally, given every 8 hours, for up to 5 days after a course of treatment.
- **Pediatrics (<18 years of age):**

MINT-ONDANSETRON SOLUTION is not indicated for this use in the pediatric population.
- **Geriatrics (≥65 years of age):**

Efficacy and tolerance in patients aged over 65 years were similar to that seen in younger adults indicating no need to alter dosage schedules in this population (See [10.3 Pharmacokinetics, Geriatrics.](#))

#### **Prevention of Post-Operative Nausea and Vomiting:**

- **Adults:**
  - 16 mg orally, administered 1 hour prior to the induction of anaesthesia.
- **Pediatrics (<18 years of age):**

MINT-ONDANSETRON SOLUTION is not indicated for this use in the pediatric population.
- **Geriatrics (≥65 years of age):**

MINT-ONDANSETRON SOLUTION is not indicated for this use in the elderly.

## **5 OVERDOSAGE**

At present there is little information concerning overdosage with ondansetron. Individual doses of 84 mg and 145 mg and total daily doses as large as 252 mg have been administered with only mild side effects. There is no specific antidote for ondansetron, therefore, in cases of suspected overdosage, symptomatic and supportive therapy should be given as appropriate.

The use of Ipecac to treat overdosage with ondansetron is not recommended as patients are unlikely to respond due to the antiemetic action of ondansetron itself.

“Sudden blindness” (amaurosis) of 2 to 3 minutes duration plus severe constipation occurred in one patient that was administered 72 mg of ondansetron intravenously as a single dose. Hypotension (and faintness) occurred in another patient that took 48 mg of oral ondansetron. Following infusion of 32 mg over only a 4-minute period, a vasovagal episode with transient second-degree heart block was observed. Neuromuscular abnormalities, autonomic instability, somnolence, and a brief generalized tonic-clonic seizure (which resolved after a dose of benzodiazepine) were observed in a 12 months’ old infant who ingested seven or eight 8-mg ondansetron tablets (approximately forty times the recommended 0.1-0.15 mg/kg dose for a pediatric patient). In all instances, the events resolved completely.

Ondansetron prolongs QT interval in a dose-dependent fashion (see [10.2 Pharmacodynamics](#)).

ECG monitoring is recommended in cases of overdose.

Cases consistent with serotonin syndrome have been reported in young children following oral overdose.

For management of a suspected drug overdose, contact your regional poison control centre.

## 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

**Table 1– Dosage Forms, Strengths, Composition and Packaging**

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	Oral solution / 4 mg / 5 ml ondansetron (as hydrochloride dihydrate)	Sodium benzoate, citric acid monohydrate, sodium citrate, liquid sorbitol (non-crystallizing), strawberry flavour, purified water.

MINT-ONDANSETRON SOLUTION contains 4 mg / 5 mL of ondansetron base in the form of ondansetron hydrochloride dihydrate. MINT-ONDANSETRON SOLUTION is sucrose-free and is sweetened with sorbitol.

MINT-ONDANSETRON SOLUTION 4 mg / 5 mL (as ondansetron hydrochloride dihydrate) is supplied in 50 mL bottles. The product is supplied with an accompanying 2.5 mL / 5 mL double-sided spoon as the dosing device.

## 7 WARNINGS AND PRECAUTIONS

### General

MINT-ONDANSETRON SOLUTION (ondansetron hydrochloride dihydrate) is not effective in preventing motion-induced nausea and vomiting.

### Cardiovascular

**QTc Interval Prolongation:** Ondansetron prolongs the QT interval (see [10.2 Pharmacodynamics, Electrocardiography](#)). The magnitude of QTc prolongation will depend on the peak serum ondansetron concentration (C<sub>max</sub>), which is substantially determined by the route of administration, the dose and the infusion rate of intravenous ondansetron. In addition, post-marketing cases of torsade de pointes have been reported in patients using ondansetron. Torsade de pointes is a polymorphic ventricular tachyarrhythmia. Generally, the risk of torsade de pointes increases with the magnitude of QTc prolongation produced by the drug. Torsade de pointes may be asymptomatic or experienced by the patient as dizziness, palpitations, syncope, or seizures. If sustained, torsade de pointes can progress to ventricular fibrillation and sudden cardiac death.



Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to either QT prolongation or electrolyte abnormalities. See [9.4 Drug-Drug Interactions](#).

Hypokalaemia, hypocalcaemia and hypomagnesemia should be corrected prior to ondansetron administration.

Additional risk factors for torsade de pointes in the general population include, but are not limited to, the following:

- female gender;
- age 65 years or older;
- baseline prolongation of the QT/QTc interval;
- presence of genetic variants affecting cardiac ion channels or regulatory proteins;
- family history of sudden cardiac death at <50 years;
- cardiac disease (e.g., myocardial ischemia or infarction, left ventricular hypertrophy, cardiomyopathy, conduction system disease);
- history of arrhythmias (especially ventricular arrhythmias, atrial fibrillation, or recent conversion from atrial fibrillation);
- bradycardia (<50 beats per minute);
- acute neurological events (e.g., intracranial or subarachnoid haemorrhage, stroke, intracranial trauma);
- nutritional deficits (e.g., eating disorders, extreme diets);
- diabetes mellitus;
- autonomic neuropathy.

#### **Myocardial Ischemia and Coronary Artery Spasm:**

Ondansetron can cause coronary artery vasospasm and myocardial ischemia which may lead to myocardial infarction. In some cases, the symptoms appeared immediately after IV infusion, or shortly after oral administration, including after low doses in patients without significant known pre-existing cardiovascular disease or other risk factors. Caution is advised during and after ondansetron administration, and close monitoring is recommended in patients with known or suspected ischemic or vasospastic coronary artery disease or other significant underlying cardiovascular disease.

#### **Driving and Operating Machinery**

In psychomotor testing ondansetron does not impair performance nor cause sedation.

#### **Gastrointestinal**

As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration.

## Hepatic/Biliary/Pancreatic

Abnormal liver function test results have been reported, as well as liver failure in clinical trial cancer patients. See [8.2 Clinical Trial Adverse Reactions, Hepatic](#); and [8.5 Post-Market Adverse Reactions](#).

## Immune

Cross-reactive hypersensitivity has been reported between different 5-HT<sub>3</sub> antagonists. Patients who have experienced hypersensitivity reactions to one 5-HT<sub>3</sub> antagonist have experienced more severe reactions upon being challenged with another drug of the same class. The use of a different 5-HT<sub>3</sub> receptor antagonist is not recommended as a replacement in cases in which a patient has experienced even a mild hypersensitivity type reaction to another 5-HT<sub>3</sub> antagonist.

## Neurologic

**Serotonin syndrome/Neuroleptic Malignant Syndrome:** Cases of life-threatening serotonin syndrome or neuroleptic malignant syndrome-like events have been reported with 5-HT<sub>3</sub> receptor antagonist antiemetics, including ondansetron hydrochloride, when given in combination with other serotonergic and/or neuroleptic drugs. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea). As these syndromes may result in potentially life-threatening conditions, treatment should be discontinued if such events occur and supportive symptomatic treatment should be initiated. If concomitant treatment of MINT-ONDANSETRON SOLUTION with a drug affecting the serotonergic neurotransmitter system is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see [9 DRUG INTERACTIONS](#)).

## Reproductive Health: Female and Male Potential

Pregnancy status should be verified for females of reproductive potential prior to starting the treatment with MINT-ONDANSETRON SOLUTION.

Females of reproductive potential should be advised that it is possible that MINT-ONDANSETRON SOLUTION can cause harm to the developing fetus. Sexually active females of reproductive potential should use effective contraception (methods that result in less than 1%

pregnancy rates) when using MINT-ONDANSETRON SOLUTION and for two days after stopping treatment with MINT-ONDANSETRON SOLUTION.

## **7.1 Special Populations**

### **7.1.1 Pregnant Women**

The use of ondansetron in pregnancy is not recommended. Ondansetron use during early pregnancy has been associated with a small increase in orofacial malformations. Despite some limitations in methodology, several human epidemiological studies noted an increase in orofacial clefts in infants of women administered ondansetron during the first trimester of pregnancy. Regarding cardiac malformations, the epidemiological studies showed conflicting results.

Ondansetron is not teratogenic in animals (see 16 [NON-CLINICAL TOXICOLOGY, Reproductive and Developmental Toxicology](#)).

### **7.1.2 Breast-feeding**

Ondansetron is excreted in the milk of lactating rats. It is not known if it is excreted in human milk, however, nursing is not recommended during treatment with ondansetron.

### **7.1.3 Pediatrics**

Insufficient information is available to provide dosage recommendations for children 3 years of age or younger.

### **7.1.4 Geriatrics**

Early phase I studies in healthy elderly volunteers showed a slight age-related decrease in clearance, and an increase in half-life of ondansetron. A greater effect on QTcF is predicted in patients  $\geq 75$  years of age compared to young adults, based on exposure-response modelling. See [10.3 Pharmacokinetics, Geriatrics](#).

## **8 ADVERSE REACTIONS**

### **8.2 Clinical Trial Adverse Reactions**

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Ondansetron has been administered to over 2500 patients worldwide in controlled clinical trials and has been well tolerated.

The most frequent adverse events reported in controlled clinical trials were headache (11%) and constipation (4%). Other adverse events include sensations of flushing or warmth (< 1%).

**Cardiovascular:**

There have been rare reports of tachycardia, angina (chest pain), bradycardia, hypotension, syncope and electrocardiographic alterations.

**Central Nervous System:**

There have been rare reports of seizures. Movement disorders and dyskinesia have been reported in two large clinical trials of ondansetron at a rate of 0.1 – 0.3%.

**Dermatological:**

Rash has occurred in approximately 1% of patients receiving ondansetron.

**Eye Disorder:**

Rare cases of transient visual disturbances (e.g. blurred vision) have been reported during or shortly after intravenous administration of ondansetron, particularly at rates equal to or greater than 30 mg in 15 minutes.

**Hepatic / Biliary / Pancreatic**

There were transient increases of SGOT and SGPT of over twice the upper limit of normal in approximately 5% of patients. These increases did not appear to be related to dose or duration of therapy. There have been reports of liver failure and death in patients with cancer receiving concurrent medications including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. The etiology of the liver failure is unclear.

**Hypersensitivity:**

Rare cases of immediate hypersensitivity reactions sometimes severe, including anaphylaxis, bronchospasm, urticaria and angioedema have been reported.

**Local Reactions:**

Pain, redness and burning at the site of injection have been reported.

**Metabolic:**

There have been rare reports of hypokalaemia.

**Other:**

There have been reports of abdominal pain, weakness, and xerostomia.

**8.5 Post-Market Adverse Reactions**

Over 250 million patient treatment days of ondansetron have been supplied since the launch of the product worldwide. The following events have been spontaneously reported during post-approval use of ondansetron, although the link to ondansetron cannot always be clearly established.

The adverse event profiles in children and adolescents were comparable to that seen in adults.

**Immune Disorders:**

Rare cases of hypersensitivity reactions, sometimes severe (e.g., laryngeal oedema, stridor, laryngospasm and cardiopulmonary arrest) have also been reported.

**Cardiovascular Disorders:**

There have been rare reports (< 0.01%) of myocardial infarction, myocardial ischemia, angina, chest pain with or without ST segment depression, arrhythmias (including ventricular or supraventricular tachycardia, premature ventricular contractions, and atrial fibrillation), electrocardiographic alterations (including second degree heart block), palpitations and syncope.

Rarely and predominantly with intravenous ondansetron, transient ECG changes including QTc interval prolongation, Torsade de Pointes, ventricular fibrillation, coronary artery spasm, myocardial ischemia, cardiac arrest, and sudden death have been reported (see [7 WARNINGS AND PRECAUTIONS, Cardiovascular](#)).

**Eye Disorder:**

There have been very rare cases of transient blindness following ondansetron treatment, generally within the recommended dosing range and predominantly during intravenous administration.

The majority of blindness cases reported resolved within 20 minutes. Although most patients had received chemotherapeutic agents, including cisplatin a few cases of transient blindness occurred following ondansetron administration for the treatment of post-operative nausea or vomiting and in the absence of cisplatin treatment. Some cases of transient blindness were reported as cortical in origin.

**Hepatic / Biliary / Pancreatic**

Occasional asymptomatic increases in liver function tests have been reported.

**Nervous System Disorders:**

Transient episodes of dizziness (< 0.1%) have been reported predominantly during or upon completion of IV infusion of ondansetron.

Uncommon reports (< 1%) suggestive of extrapyramidal reactions including oculogyric crisis/dystonic reactions (e.g., oro-facial dyskinesia, opisthotonos, tremor, etc.), movement disorders and dyskinesia have been reported without definitive evidence of persistent clinical sequelae.

Serotonin syndrome and neuroleptic malignant syndrome-like events have been reported with 5-HT<sub>3</sub> receptor antagonist antiemetics, including ondansetron, when given in combination with other serotonergic and/or neuroleptic drugs (see [7 WARNINGS AND PRECAUTIONS, Neurologic](#)).

**Respiratory, Thoracic and Mediastinal Disorders:**

There have also been rare reports of hiccups.

### **Skin and Subcutaneous Tissue Disorders:**

Very rare reports have been received for bullous skin and mucosal reactions, including fatal cases. These reports include toxic skin eruptions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis and have occurred in patients taking other medications that can be associated with bullous skin and mucosal reactions.

## **9 DRUG INTERACTIONS**

### **9.1 Serious Drug Interactions**

#### **Serious Drug Interactions** (see [9.4 Drug-Drug Interactions](#))

- Apomorphine (see [2 CONTRAINDICATIONS](#))
- QTc-Prolonging drugs
- Serotonergic agents

### **9.2 Drug Interactions Overview**

Ondansetron is extensively metabolised by multiple hepatic cytochrome P450 enzymes (predominantly CYP3A4, also CYP2D6 and CYP1A2), and clearance is reduced in hepatic insufficiency (see [10.3 Pharmacokinetics, Hepatic Insufficiency](#)). CYP 3A4 inducers can increase ondansetron clearance (see [9.4 Drug-Drug Interactions, CYP 3A4 Inducers](#)).

Ondansetron does not itself appear to induce or inhibit the cytochrome P<sub>450</sub> drug-metabolizing enzyme system of the liver.

### **9.4 Drug-Drug Interactions**

**CYP 3A4 inducers:** Despite the multiplicity of metabolic enzymes capable of metabolising ondansetron which might be expected compensate for an increase or decrease in enzyme activity, patients treated with inducers of CYP3A4 (i.e. phenytoin, carbamazepine, and rifampicin) demonstrated an increase in oral clearance of ondansetron and a decrease in ondansetron blood concentrations.

In a pharmacokinetic study of 16 epileptic patients maintained chronically on carbamazepine or phenytoin (CYP 3A4 inducers), reduction in AUC, C<sub>max</sub> and T<sub>½</sub> of ondansetron was observed. This resulted in a significant increase in clearance. However, on the basis of the inter-subject variability in the available data, no dosage adjustment can be recommended.

**CYP 2D6 inhibitors:** No effect in ondansetron clearance secondary to enzyme inhibition has been identified to date.

**QTc-Prolonging Drugs:** The concomitant use of MINT-ONDANSETRON SOLUTION with another QTc- prolonging drug should be carefully considered to determine that the therapeutic benefit outweighs the potential risk. Drugs that have been associated with QTc interval prolongation and/or torsade de pointes include, but are not limited to, the examples in the following list.

Chemical/pharmacological classes are listed if some, although not necessarily all, class members have been implicated in QTc prolongation and/or torsade de pointes:

- Class IA antiarrhythmics (e.g., quinidine, procainamide, disopyramide);
- Class III antiarrhythmics (e.g., amiodarone, sotalol, ibutilide, dronedarone);
- Class 1C antiarrhythmics (e.g., flecainide, propafenone);
- antiemetics (e.g., dolasetron, palonosetron, granisetron, droperidol, chlorpromazine, prochlorperazine);
- tyrosine kinase inhibitors (e.g., vandetanib, sunitinib, nilotinib, lapatinib);
- antipsychotics (e.g., chlorpromazine, pimozide, haloperidol, ziprasidone);
- antidepressants (e.g., citalopram, fluoxetine, venlafaxine, tricyclic/tetracyclic antidepressants e.g., amitriptyline, imipramine, maprotiline);
- opioids (e.g., methadone);
- domperidone;
- macrolide antibiotics and analogues (e.g., erythromycin, clarithromycin, telithromycin, tacrolimus);
- quinolone antibiotics (e.g., moxifloxacin, levofloxacin, ciprofloxacin);
- antimalarials (e.g., quinine, chloroquine);
- azole antifungals (e.g., ketoconazole, fluconazole, voriconazole);
- histone deacetylase inhibitors (e.g., vorinostat);
- beta-2 adrenoceptor agonists (e.g., salmeterol, formoterol).

**Drugs that Cause Electrolyte Abnormalities:** The use of MINT-ONDANSETRON SOLUTION with drugs that can disrupt electrolyte levels should be avoided. Such drugs include, but are not limited to, the following:

- loop, thiazide, and related diuretics;
- laxatives and enemas;
- amphotericin B;
- high dose corticosteroids.

The above lists of potentially interacting drugs are not comprehensive. Current information sources should be consulted for newly approved drugs that prolong the QTc interval or cause electrolyte disturbances, as well as for older drugs for which these effects have recently been established.

**Tramadol:** Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.

**Apomorphine:** Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated (see [2 CONTRAINDICATIONS](#)).

**Serotonergic Drugs:** As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may occur with 5-HT<sub>3</sub> receptor antagonist antiemetic treatment when

given in combination with other agents that may affect the serotonergic neurotransmitter system [including triptans, SSRIs, SNRIs, lithium, sibutramine, fentanyl and its analogues, dextromethorphan, tramadol, tapentadol, meperidine, methadone and pertazocine or St. John's Wort (*Hypericum perforatum*)] and with drugs which impair metabolism of serotonin (such as MAOIs, including linezolid (an antibiotic which is a reversible non-selective MAOI) and methylene blue) (see [7 WARNINGS AND PRECAUTIONS, Neurologic](#)).

### **9.5 Drug-Food Interactions**

Interactions with food have not been established.

### **9.6 Drug-Herb Interactions**

Interactions with herbal products have not been established.

### **9.7 Drug-Laboratory Test Interactions**

Interactions with laboratory tests have not been established.

## **10 CLINICAL PHARMACOLOGY**

### **10.1 Mechanism of Action**

MINT-ONDANSETRON SOLUTION (ondansetron hydrochloride dihydrate) is a selective antagonist of the serotonin receptor subtype, 5-HT<sub>3</sub>. Its precise mode of action in the control of chemotherapy induced nausea and vomiting is not known.

Cytotoxic chemotherapy and radiotherapy are associated with the release of serotonin (5-HT) from enterochromaffin cells of the small intestine, presumably initiating a vomiting reflex through stimulation of 5-HT<sub>3</sub> receptors located on vagal afferents. Ondansetron may block the initiation of this reflex. Activation of vagal afferents may also cause a central release of serotonin from the chemoreceptor trigger zone of the area postrema, located on the floor of the fourth ventricle. Thus, the antiemetic effect of ondansetron is probably due to the selective antagonism of 5-HT<sub>3</sub> receptors on neurons located in either the peripheral or central nervous systems, or both.

The mechanisms of ondansetron's antiemetic action in post-operative nausea and vomiting are not known.

### **10.2 Pharmacodynamics**

Serotonin receptors of the 5-HT<sub>3</sub> type are present both peripherally and on vagal nerve terminals. Ondansetron probably acts by preventing activation of these receptors or receptors located in other regions of the central nervous system. Both the peripheral and central nervous systems appear to be involved since both abdominal vagotomy and microinjection of ondansetron and other 5-HT<sub>3</sub> antagonists directly into the area postrema eliminate cisplatin-induced emesis, while 5-HT<sub>1</sub>-like (methiothepin maleate) and 5-HT<sub>2</sub> (ketanserin) antagonists have no effect.



Ondansetron is highly selective for 5-HT<sub>3</sub> receptors and shows negligible binding to other receptors such as 5-HT<sub>1</sub>-like, 5-HT<sub>2</sub>, α<sub>1</sub> and α<sub>2</sub> adrenoceptors, β<sub>1</sub> and β<sub>2</sub> adrenoceptors, D<sub>1</sub> and D<sub>2</sub> muscarinic, nicotinic, GABA<sub>A</sub>, H<sub>1</sub> and H<sub>2</sub> receptors.

The pharmacological specificity of ondansetron may explain the observed lack of extrapyramidal side effects often seen following similar therapy with metoclopramide, which preferentially binds to dopamine receptors of the D<sub>2</sub> subtype.

*In vivo* pharmacodynamic studies have investigated the effects of ondansetron on gastric emptying, small bowel transit time and oesophageal motility.

Both oral (16 mg tid) and intravenous (5-10 mg) doses of ondansetron failed to produce a significant effect on gastric emptying in both healthy volunteers and in patients suffering from delayed gastric emptying. However, in one study intravenous doses of 8 mg did increase gastric emptying in over half the volunteers tested.


Intravenous infusion of either 1 mg or 5 mg ondansetron tended to increase small bowel transit times and single intravenous doses of 10 mg ondansetron have been reported to decrease sphincter pressure in the lower oesophagus in some subjects.

### **Electrocardiography**

The effect of ondansetron on the QTc interval was evaluated in a double blind, randomized, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women. Ondansetron was tested at single doses of 8 mg and 32 mg infused intravenously over 15 minutes. At the highest tested dose of 32 mg, prolongation of the Fridericia-corrected QTc interval ( $QT/RR^{0.33}=QTcF$ ) was observed from 15 min to 4 h after the start of the 15 min infusion, with a maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction of 19.6 (21.5) msec at 20 min. At the lower tested dose of 8 mg, QTc prolongation was observed from 15 min to 1 h after the start of the 15 minute infusion, with a maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction of 5.8 (7.8) msec at 15 min. The magnitude of QTc prolongation with ondansetron is expected to be greater if the infusion rate is faster than 15 minutes. The 32 mg intravenous dose of ondansetron must not be administered.

No treatment-related effects on the QRS duration or the PR interval were observed at either the 8 or 32 mg dose.

### LS Mean Difference (90% CI) in QTcF Interval Between Treatment and Placebo Over Time



An ECG assessment study has not been performed for orally administered ondansetron. On the basis of pharmacokinetic-pharmacodynamic modelling, an 8 mg oral dose of ondansetron is predicted to cause a mean QTcF increase of 0.7 ms (90% CI -2.1, 3.3) at steady-state, assuming a mean maximal plasma concentration of 24.7 ng/mL (95% CI 21.1, 29.0).

The magnitude of QTc prolongation at the recommended 5 mg/m<sup>2</sup> dose in pediatrics has not been studied, but pharmacokinetic-pharmacodynamic modelling predicts a mean increase of 6.6 ms (90% CI 2.8, 10.7) at maximal plasma concentrations.

### 10.3 Pharmacokinetics


#### Absorption

- Oral administration


Pharmacokinetic studies in human volunteers showed peak plasma levels of 20-30 ng/mL at around 1½ hours after an 8 mg oral dose of ondansetron. Repeat dosing of an 8 mg tablet every 8 hours for 6 days increased the peak plasma value to 40 ng/mL.

#### Mean Plasma Concentration-Time Curve for Ondansetron 8 mg and 32 mg doses:

##### Linear Scale



## Semi-logarithmic Scale



### Distribution:

The absolute bioavailability of ondansetron in humans was approximately 60% and the plasma protein binding was approximately 73%.

See also [16. NON-CLINICAL TOXICOLOGY, Non-clinical pharmacokinetics](#).

### Metabolism:

*In vitro* metabolism studies have shown that ondansetron is a substrate for human hepatic cytochrome P<sub>450</sub> enzymes, including CYP1A2, CYP2D6 and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 played the predominant role. Because of the multiplicity of metabolic enzymes capable of metabolising ondansetron, it is likely that inhibition or loss of one enzyme (e.g. CYP2D6 enzyme deficiency) will be compensated by others and may result in little change in overall rates of ondansetron clearance (see [9.4 Drug-Drug Interactions, CYP 3A4 inducers](#)).

### Elimination

Following extensive metabolism of an orally or intravenously administered, ondansetron is excreted in the urine and feces. In humans, less than 10% of the dose is excreted unchanged in the urine. The major urinary metabolites are glucuronide conjugates (45%), sulphate conjugates (20%) and hydroxylation products (10%).

The half-life of ondansetron after either an 8 mg oral dose or intravenous dose was approximately 3-4 hours and may be extended to 6-8 hours in the elderly.

## Special Populations and Conditions

- **Geriatrics**

Early Phase I studies in healthy elderly volunteers showed a slight age-related decrease in clearance, and an increase in half-life of ondansetron. However, wide inter-subject variability resulted in considerable overlap in pharmacokinetic parameters between young (< 65 years of age) and elderly subjects (≥ 65 years of age) and there were no overall differences in safety or efficacy observed between young and elderly cancer patients enrolled in CINV clinical trials. (See [4.2 Recommended Dose and Dosage Adjustment, Use in Elderly](#))

Based on more recent ondansetron plasma concentrations and exposure-response modelling, a greater effect on QTcF is predicted in patients ≥75 years of age compared to young adults. (See [4.2 Recommended Dose and Dosage Adjustment, Use in Elderly](#))

- **Genetic Polymorphism**

**CYP 2D6:** The elimination half-life and plasma levels of a single 8 mg intravenous dose of ondansetron did not differ between subjects classified as poor and extensive metabolisers of sparteine and debrisoquine (CYP 2D6 substrates). No alteration of daily dosage or frequency of ondansetron dosing is recommended for patients known to be CYP 2D6 poor metabolisers.

- **Hepatic Insufficiency**

The clearance of an 8 mg intravenous dose of ondansetron hydrochloride was significantly reduced and the serum half-life significantly prolonged in subjects with severe impairment of hepatic function. In patients with moderate or severe impairment of hepatic function, reductions in dosage are therefore recommended and a total daily dose of 8 mg should not be exceeded. This may be given as a single intravenous or oral dose. There is no experience in patients who are clinically jaundiced.

- **Renal Insufficiency**

No alteration of daily dosage, frequency of dosing, or route of administration is required in patients with impaired renal function.

## 11 STORAGE, STABILITY AND DISPOSAL

MINT-ONDANSETRON SOLUTION should be stored upright between 15°C and 30°C and should not be refrigerated. Keep out of the reach and sight of children.

## PART II: SCIENTIFIC INFORMATION

### 13 PHARMACEUTICAL INFORMATION


#### Drug Substance

Proper name: ondansetron hydrochloride dihydrate  
Chemical name: (3*RS*)-9-Methyl-3-[(2-methyl-1*H*-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride hydrate

Molecular formula and molecular mass:

$C_{18}H_{19}N_3O \cdot HCl \cdot 2H_2O$  (hydrochloride dihydrate), 365.9 g/mol

Structural formula:



Physicochemical properties:

Description and Solubility:

Ondansetron hydrochloride dihydrate is a white to off-white powder. It is sparingly soluble in water and ethanol (96%), soluble in methanol and slightly soluble in methylene chloride. The melting point of ondansetron hydrochloride dihydrate is 178.5–179.5°C and pKa is 7.4. Ondansetron hydrochloride dihydrate is non-hygroscopic.

### 14 CLINICAL TRIALS

#### 14.1 Trial Design and Study Demographics

The clinical data on which the original indication was authorized is not available.

#### 14.2 Study Results

Clinical trial results showing the number and percentage of patients exhibiting a complete response to ondansetron (0 emetic episodes) are shown in the tables below for both post-operative and chemotherapy induced emesis.

	Oral Prevention		
Dose	Ondansetron 16 mg od	Placebo	p value
# of patients	253	250	
Treatment Response: 0 emetic episodes	126 (50%)	79 (32%)	< 0.001

\* The majority of patients included in the prevention and treatment of post-operative nausea and vomiting studies using ondansetron have been adult women receiving balanced anaesthesia for gynaecological surgery.

	Oral Treatment		
Dose	Ondansetron 8 mg PO tid*	Metoclopramide 10 mg PO tid*	p value
# of patients	38	44	
Treatment Response 0 emetic episodes	37 (97%)	20 (45%)	< 0.001

\* results from a study of adult male and female patients receiving single high dose radiotherapy (800 to 1,000 cGy) over an anterior or posterior field size of  $\geq 80$  cm<sup>2</sup> to the abdomen.

\* Patients received the first dose of ondansetron 8 mg tablets or metoclopramide (10 mg) 1-2 hours before radiotherapy. If radiotherapy was given in the morning, 2 additional doses of study treatment were given (1 tablet late afternoon and 1 tablet before bedtime). If radiotherapy was given in the afternoon, patients took only 1 further tablet that day before bedtime. Patients continued oral medication on 3 times a day basis for 3-5 days.

## 16 NON-CLINICAL TOXICOLOGY

### Non-clinical pharmacodynamics

**Ferret model:** The ferret provides an excellent model for demonstrating the antiemetic action of drugs. Emesis can be induced by antineoplastic drugs or whole body irradiation. Behavioural changes associated with these treatments are noted in these animals and may also provide a parallel for the human experience of nausea.

**CINV:** The antiemetic action of ondansetron has been evaluated in both male and female ferrets given cisplatin (9-10 mg/kg), cyclophosphamide (200 mg/kg) or irradiation (2 and 8 Gy, 250 kV). Intravenous doses of ondansetron (0.1-1 mg/kg) abolished cisplatin-induced emesis for up to 2 hours. In cyclophosphamide-induced emesis, subcutaneous doses of 0.5 mg/kg ondansetron completely eliminated vomiting, significantly reduced retching and delayed the onset of these responses.

**RINV:** The radiation-induced emesis, 0.5 mg/kg ondansetron alone completely and rapidly eliminated retching and vomiting.

**Dexamethasone:** The antiemetic effects of ondansetron (0.1 mg/kg) in combination with dexamethasone (2-5 mg/kg) were potentiated in ferrets with cyclophosphamide-induced emesis, compared with ondansetron alone. Ondansetron with dexamethasone produced a significant reduction in retching (65%) and vomiting (72%).

**Gastric emptying:** Among its secondary effects, ondansetron has also been shown to cause a dose-dependent increase in the rate of gastric emptying in the guinea pig, which is significant at doses of 0.01-0.1 mg/kg. As gastric stasis is frequently associated with nausea, stimulation of gastric motility may be a beneficial action of ondansetron. In the cat, dog and monkey, ondansetron has little effect on heart rate, blood pressure or ECG at intravenous doses up to 3 mg/kg.

**QT-prolongation:** A study in cloned human cardiac ion channels has shown ondansetron has the potential to affect cardiac repolarisation via blockade of hERG potassium channels at clinically relevant concentrations. Dose-dependent QT prolongation has been observed in a thorough QT study in human volunteers (see [10.2 Pharmacodynamics – Electrocardiography](#)).

**Non-clinical pharmacokinetics:** In mice, rats, rabbits and dogs dosed at 1 mg/kg orally and/or intravenously, the plasma half-life of ondansetron was less than 1 hour, but the half-lives of its metabolites were significantly longer. Peak plasma concentrations of ondansetron in rats and dogs ranged from 351 to 419 ng/mL for the IV dose and 8 to 15 ng/mL for the oral dose. Plasma levels were linear over a 30-fold dose range. In repeat-dose studies there was no apparent accumulation of ondansetron.

Ondansetron is almost completely absorbed in animals and is rapidly metabolized by N-demethylation and hydroxylation of the indole ring, followed by conjugation with glucuronic acid and sulphate. There is significant first-pass metabolism after oral doses.

Ondansetron and its metabolites are rapidly and widely distributed in tissues, reaching higher levels than the corresponding plasma levels. In the rat and dog, ondansetron binds reversibly to tissues containing melanin and elastin. In rats and man, plasma protein binding is about 73%, while it is slightly lower in the dog (60%). Ondansetron and its metabolites cross the blood-brain barrier to only a slight extent.

### General Toxicology:

- **Acute Toxicity**



Single doses of ondansetron up to the LD<sub>50</sub> in mice and in rats were generally well tolerated. Reactions, including tremor and convulsive behaviour, occurred only at near lethal levels.

**Table 4:**

Species	LD <sub>50</sub> (mg/kg)	
	Oral	IV
Mice	10-30	1.0-2.5
Rats	100-150	15-20

All deaths resulted from the acute effects of treatment, the observed clinical signs being consistent with the central nervous system effects associated with behavioural depression. These effects were not associated with any apparent histopathological changes in the brain. No target organ toxicity was identified.

- **Long term Toxicity**

**Table 5: Subacute Toxicity Studies**

Species	Route	Dose (mg/kg/day)	Duration of Study	Results
Rats	Oral	160	7 weeks	Well tolerated
	IV	12	5 weeks	Well tolerated
Dogs	Oral	7.5-25	5 weeks	Transient post-dosing clinical reactions associated with behavioural depression (at highest dose levels)
	IV	2-8	5 weeks	

Maximum daily dose levels in rats were found to be higher when doses were gradually increased. Identical doses were rapidly lethal to rats not previously exposed to ondansetron. Post-dosing reactions, in both rats and dogs, included ataxia, exophthalmia, mydriasis, tremor and respiratory changes. Increases in liver enzymes (SGPT and SGOT) were noted at high dose levels. Dogs dosed at 6.75 mg/kg/day intravenously exhibited vein irritancy in the form of constriction and thickening, creating resistance to needle penetration. The changes were noted after seven days treatment but were reversed by decreasing the dose concentration.

**Table 6: Chronic Toxicity**

Species	Duration	Max. no-effect Dose (mg/kg/day)	Effects
Rat	18 months	1	Usually transient and restricted to highest dose
Dog	12 months	12	

**Carcinogenicity****Table 7: Carcinogenicity Studies**

Species	Route	Dose (mg/kg/day)	Duration of Study	Results
Mice	Oral	1-40 (max. oral dose 30)	2 years	No treatment related increases in tumour incidence.
Rats	Oral	1-25 (max. oral dose 10)	2 years	Proportion of benign/malignant tumours also remained Consistent with the pathological background of the Animals studied.

There was no evidence of a tumourigenic effect of ondansetron in any tissue.

**Mutagenicity**

No evidence of mutagenicity was observed in microbial mutagen tests using mutant strains of *Salmonella typhimurium*, *Escherichia coli* or *Saccharomyces cerevisiae*, with or without a rat-liver post-mitochondrial metabolizing system.

There was also no evidence of damage to genetic material noted in in vitro V-79 mammalian cell mutation studies, in vitro chromosome aberration tests using human peripheral lymphocytes, or in vivo chromosome aberration assays in mouse bone marrow.

**Reproductive and Developmental Toxicology:**

Ondansetron was not teratogenic in rats and rabbits at dosages up to the maximum non-convulsive level, (rat: 15 mg/kg/day, rabbit: 30 mg/kg/day; the maternal dose was approximately 6 and 24 times the maximum recommended human oral dose of 24 mg/day, respectively, based on body surface area). No adverse effects on pregnancy or fetal and post-natal development were detected in rats and no fetal abnormalities were observed in rabbits after oral administration of ondansetron.

A slight maternal toxicity was observed at the highest dose level in intravenous organogenesis (4.0 mg/kg/day) studies in the rabbit. Effects included maternal body weight loss and increased incidence of early fetal death. In a rat fertility study, there was a dose-related decrease in the proportion of surviving pups of the F2 generation; however, the significance of this is unclear.

Administration of ondansetron to pregnant rats and rabbits indicated there was fetal exposure to low levels of ondansetron and its metabolites. Ondansetron is retained in the fetal eye presumably bound to melanin. In rats, the transfer of ondansetron and its metabolites into breast milk was extensive. The concentration of unchanged ondansetron in breast milk was higher than in corresponding plasma samples.

Daily administration of ondansetron at dosages up to 15 mg/kg/day to pregnant rats (a maternal dose of approximately 6 times the maximum recommended human oral dose of 24 mg/day, based on body surface area) from day 17 of pregnancy to litter day 22 had no effects on pregnancy of the parental generation or on post-natal development and mating of the F1 generation. Fetal development of the F2 generation was comparable to controls; however, the number of implantations and viable fetuses was reduced in the highest dosage group when compared with controls.

## 17 SUPPORTING PRODUCT MONOGRAPHS

1. ZOFRAN<sup>®</sup>, oral solution, 4 mg / 5 mL, submission control no. 252778, Product Monograph, Novartis Pharmaceuticals Canada Inc. November 9, 2021.

## **PATIENT MEDICATION INFORMATION**

### **READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE**

#### **P<sup>r</sup>MINT-ONDANSETRON SOLUTION**

#### **ondansetron oral solution**

Read this carefully before you start taking **MINT-ONDANSETRON SOLUTION** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **MINT-ONDANSETRON SOLUTION**.

#### **What is MINT-ONDANSETRON SOLUTION used for?**

##### **Children (4 to 17 years of age):**

MINT-ONDANSETRON SOLUTION is used to treat nausea and vomiting during certain types of chemotherapy.

##### **Adults (18 to 64 years of age):**

MINT-ONDANSETRON SOLUTION is used:

- to prevent nausea and vomiting during certain types of chemotherapy and radiotherapy, and
- to prevent nausea and vomiting after surgery.

##### **Geriatrics (65 years of age and older):**

MINT-ONDANSETRON SOLUTION is used to prevent nausea and vomiting during chemotherapy and radiotherapy.

#### **How does MINT-ONDANSETRON SOLUTION work?**

MINT-ONDANSETRON SOLUTION is a medication known as an antiemetic. Treatments such as cancer chemotherapy and radiotherapy are associated with the release of a natural substance (serotonin). The release of serotonin, can make you feel sick and vomit. The way that MINT-ONDANSETRON SOLUTION works is not known, but it is thought to help stop the effects of serotonin to reduce the effects of nausea and vomiting.

#### **What are the ingredients in MINT-ONDANSETRON SOLUTION?**

- Medicinal ingredient: ondansetron hydrochloride dihydrate
- Non-medicinal ingredients: Sodium benzoate, citric acid monohydrate, sodium citrate, liquid sorbitol (non-crystallizing), strawberry flavour and purified water.

**MINT-ONDANSETRON SOLUTION comes in the following dosage forms:**

- Oral solution: 4 mg / 5 mL of ondansetron (as ondansetron hydrochloride dihydrate).

**Do not use MINT-ONDANSETRON SOLUTION if:**

- You are allergic to ondansetron hydrochloride dihydrate, or to any other ingredients in MINT-ONDANSETRON SOLUTION.
- You are taking a medicine called apomorphine (used to treat Parkinson's disease)

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take MINT-ONDANSETRON SOLUTION. Talk about any health conditions or problems you may have, including if you:**

- have had an allergic reaction to medicines that are similar to MINT-ONDANSETRON SOLUTION such as medicines containing granisetron or palonosetron.
- are pregnant or planning to become pregnant. MINT-ONDANSETRON SOLUTION is not recommended for use during pregnancy.
- are breast feeding or planning to breastfeed. MINT-ONDANSETRON SOLUTION can pass into your breast milk and affect your baby.
- have liver problems.
- have signs of intestinal obstruction or blockage.
- have or have had heart or blood vessel problems, including if you are at higher risk for these problems. Risk factors include, but are not limited to, if you:
  - have family members who have or have had heart or blood vessel problems,
  - smoke,
  - have high blood pressure,
  - have high cholesterol levels,
  - have diabetes, or
  - are overweight.
- are taking medications that affect the serotonin in your body (e.g., serotonergic and neuroleptic medications). If you are unsure, ask your healthcare professional.
- have QT/QTc prolongation (a heart rhythm condition) or family history of QT/QTc prolongation.
- are taking medications that may lead to QT/QTc prolongation or electrolyte imbalances. If you are unsure, ask your healthcare professional.
- have low blood levels of potassium, magnesium, or calcium.

**Other warnings you should know about:**

**Serotonin Syndrome:** MINT-ONDANSETRON SOLUTION can cause serotonin syndrome, a rare but potentially life-threatening condition. It can cause serious changes in how your brain, muscles, and digestive system work. You may develop serotonin syndrome if you take MINT-ONDANSETRON SOLUTION with certain anti-depressants or migraine medications.

Serotonin syndrome symptoms include:

- Fever, sweating, shivering, diarrhea, nausea, vomiting;
- Muscle shakes, jerks, twitches or stiffness, overactive reflexes, loss of coordination;
- Fast heartbeat, changes in blood pressure;
- Confusion, agitation, restlessness, hallucinations, mood changes, unconsciousness, and coma.

**Myocardial ischemia (lack of blood flow to the heart):** Treatment with MINT- ONDANSETRON SOLUTION can cause myocardial ischemia which can lead to a heart attack. This may happen shortly after MINT-ONDANSETRON SOLUTION administration. Some symptoms of myocardial ischemia can include sudden chest pain, pressure or discomfort, feeling faint, feeling anxious, shortness of breath, irregular heartbeat, nausea, and sudden heavy sweating. Your healthcare professional will monitor your health during and after administration of MINT- ONDANSETRON SOLUTION. However, if you notice any symptoms of myocardial ischemia, tell your healthcare professional right away. They may reduce or stop your treatment and may recommend another therapy.

**QT/QTc prolongation:** MINT-ONDANSETRON SOLUTION can affect the electrical activity of your heart known as QT/QTc prolongation. This effect can be measured with an electrocardiogram (ECG). In rare cases, QT/QTc prolongation can cause changes to the rhythm of your heart (e.g., fast, slow or irregular heartbeats). This can lead to dizziness, palpitations (sensation of rapid, pounding, or irregular heart beat), fainting, or death. You are at a higher risk if you have a heart disease, are taking certain interacting medicines, are a female, or are over the age of 65 years. It is important to follow the instructions of your healthcare professional with regard to dosing or any special tests. If you experience any symptoms of a possible heart rhythm problem, you should seek immediate medical attention.

**Severe allergic reactions:** MINT-ONDANSETRON SOLUTION can cause allergic reactions in certain individuals. Symptoms of a severe allergic reaction can include wheezing, sudden chest pain, tightness of the chest, heart throbbing, swelling of eyelids, face or lips, or develop a skin rash, skin lumps or hives. If you notice any signs of a severe allergic reaction, **contact your healthcare professional immediately. Do not take any more medicine unless your healthcare professional tells you to do so.**

**Pregnancy:**

- If you are pregnant, there are specific risks for your unborn baby that you must discuss with your healthcare professional.
- If you are able to get pregnant, you may be asked to take a pregnancy test before starting your treatment with MINT-ONDANSETRON SOLUTION
- You should use effective birth control while you are taking MINT-ONDANSETRON SOLUTION and for at least 2 days after stopping MINT-ONDANSETRON SOLUTION. Ask your healthcare professional about options of effective birth control.
- If you become pregnant while taking MINT-ONDANSETRON SOLUTION tell your healthcare professional right away.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with MINT-ONDANSETRON SOLUTION:**

- medicines called CYP3A4 inducers (e.g., phenytoin, carbamazepine, and rifampicin);
- medicines used to treat heart rhythm disorders (e.g., quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, dronedarone, flecainide, and propafenone);
- medicines used to treat vomiting and nausea called antiemetics (e.g., dolasetron, palonosetron, granisetron, droperidol, chlorpromazine, prochlorperazine, and domperidone);
- medicines called tyrosine kinase inhibitors (e.g., vandetanib, sunitinib, nilotinib, and lapatinib);
- medicines used to manage psychosis or schizophrenia called antipsychotics (e.g., chlorpromazine, pimozide, haloperidol, and ziprasidone);
- medicines used to treat depression called antidepressants (e.g., citalopram, fluoxetine, venlafaxine, tricyclic/tetracyclic antidepressants, amitriptyline, imipramine, and maprotiline);
- medicines used to treat pain called opioids (e.g., methadone and tramadol);
- medicines used to treat bacterial infections called antibiotics (e.g., erythromycin, clarithromycin, telithromycin, tacrolimus, moxifloxacin, levofloxacin, and ciprofloxacin);
- medicines used to treat malaria called antimalarials (e.g., quinine and chloroquine);
- medicines used to treat fungal infections called azole antifungals (e.g., ketoconazole, fluconazole, and voriconazole);
- medicines used to treat cancer (e.g., vorinostat);
- medicines called beta-2 adrenoceptor agonists (e.g., salmeterol and formoterol);
- medicines that can affect electrolyte levels (e.g., diuretics, laxatives, enemas, amphotericin B, and high doses of corticosteroids);
- a medicine used to treat Parkinson's Disease called apomorphine;
- medicines called serotonergic drugs that can affect the serotonin in the body (e.g., triptans, Selective Serotonin-Reuptake Inhibitors (SSRIs), Serotonin Noradrenalin Reuptake Inhibitors (SNRIs), lithium, sibutramine, fentanyl and its analogues, dextromethorphan, tramadol, tapentadol, meperidine, methadone, pertazocine, St. John's Wort (*Hypericum perforatum*), monoamine oxidase inhibitors (MAOIs), linezolid, and methylene blue).

If you are unsure about any medications you are taking, ask your healthcare professional.

**How to take MINT-ONDANSETRON SOLUTION:**

- The label on the container of your medicine should tell you how often to take your medicine and how many doses you should take each time. If not, or if you are not sure, consult your healthcare professional.



- **Do not** take more doses, or take them more often than your healthcare professional prescribes. If, however, you vomit within one hour of taking your medicine, you should take the same amount of medicine again. If vomiting persists, consult your healthcare professional.

**Usual dose:**

Take MINT-ONDANSETRON SOLUTION exactly as your healthcare professional has told you. Your healthcare professional will determine the right dose and length of MINT-ONDANSETRON SOLUTION for you. Your dose will depend on your medical condition, age, current health, and if you take certain other medications. Your healthcare professional may monitor your health throughout your treatment and may interrupt, reduce or stop your dose.

**Overdose:**

If you think you, or a person you are caring for, have taken too much MINT-ONDANSETRON SOLUTION, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

**Missed Dose:**

If you miss a dose and do not feel sick, take the next dose when it is due.

If you forget to take your medicine and feel sick or vomit, take a dose as soon as possible.

If your healthcare professional decides to stop the treatment, do not keep any leftover medicine unless your healthcare professional tells you to.

**What are possible side effects from using MINT-ONDANSETRON SOLUTION?**

These are not all the possible side effects you may have when taking MINT-ONDANSETRON SOLUTION. If you experience any side effects not listed here, tell your healthcare professional.

Some side effects may include:

- feeling of flushing or warmth;
- hiccups.

There is no need to stop taking your medicine, but you should tell your healthcare professional about these symptoms at your next visit.

If you feel unwell or have any symptoms that you do not understand, you should contact your healthcare professional immediately.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>UNCOMMON</b>			
<b>Heart problems</b> (disorders affecting your heart muscle, valves or rhythm): chest pain, chest discomfort, high blood pressure, irregular heart rhythm, shortness of breath, or fainting.			✓
<b>Seizures:</b> loss of consciousness with uncontrollable shaking, visual disturbances (e.g., blurred vision).			✓
<b>Movement disorders</b> (including dyskinesia): loss of coordination or balance, speech or limb movements, muscle spasms, difficulty walking, tremor, upward rolling of the eyes, or abnormal muscular stiffness.			✓
<b>RARE</b>			
Eye problems such as blurred vision		✓	
<b>Immediate severe allergic reaction:</b> swelling of the mouth, throat, difficulty in breathing, rash, hives, increased heart rate			✓
<b>Serotonin Syndrome:</b> a reaction which may cause feelings of agitation or restlessness, flushing, muscle twitching, involuntary eye movements, heavy sweating, high body temperature (> 38°C), or rigid muscles.			✓
<b>Liver problems:</b> yellowing of your skin and eyes (jaundice), unusual dark urine and pale stools, pain or swelling in the right upper abdomen, unusual tiredness, nausea, or vomiting.			✓

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>Hypokalemia</b> (low level of potassium in the blood): muscle weakness, muscle spasms, cramping, constipation, feeling of skipped heart beats or palpitations, fatigue, tingling, or numbness			✓
<b>Prolongation of QT interval</b> (a heart rhythm condition): irregular heartbeat, palpitations, dizziness, fainting, loss of consciousness, or seizures.			✓
<b>Hypotension</b> (low blood pressure): dizziness, fainting, light-headedness, blurred vision, nausea, or vomiting.			✓
<b>Myocardial ischemia</b> (lack of blood flow to the heart which can lead to heart attack): sudden chest pain, pressure or discomfort, feeling faint, feeling anxious, shortness of breath, irregular heartbeat, nausea, or sudden heavy sweating.			✓
<b>VERY RARE</b>			
Eye problems such as temporary blindness.		✓	
<b>Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)</b> (severe skin reactions): redness, blistering or peeling of the skin and/or inside of the lips, eyes, mouth, nasal passages or genitals, fever, chills, headache, cough, body aches, or swollen glands.			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

### **Reporting Side Effects**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### **Storage:**

MINT-ONDANSETRON SOLUTION should be stored in its bottle, upright, between 15°C and 30°C. Do not refrigerate.

Keep your medicine in a safe place out of reach and sight of children. Your medicine may harm them.

### **If you want more information about MINT-ONDANSETRON SOLUTION:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website [www.mintpharmaceuticals.com](http://www.mintpharmaceuticals.com), or by calling 1-877-398-9696.

This leaflet was prepared by Mint Pharmaceuticals Inc.

Last Revised September 13, 2022